Oncolytics Biotech

Forecast & Rating7 analysts currently cover Oncolytics Biotech, with about 71.4% giving a positive rating — meaning they expect the stock to rise. The average price target is $5.08, about 536.1% upside from the current price of $0.80. Price targets range from $2.89 to $10.09 — a wide spread, showing clear disagreement over just how much Oncolytics Biotech can rise. For you, this means most professionals who study Oncolytics Biotech closely still see room for the stock to rise. Data as of Jul 20, 2026; for reference only and not investment advice.